Serving hundreds of leading biopharmaceutical companies globally:

Generated: September 23, 2018

DrugPatentWatch Database Preview

Smithkline Beecham Company Profile

« Back to Dashboard

What is the competitive landscape for SMITHKLINE BEECHAM, and when can generic versions of SMITHKLINE BEECHAM drugs launch?

SMITHKLINE BEECHAM has six approved drugs.

There are two US patents protecting SMITHKLINE BEECHAM drugs.

Summary for Smithkline Beecham

US Patents:	2
Tradenames:	6
Ingredients:	6
NDAs:	6
Drug Master File Entries:	2
Patent Litigation for Smithkline Beecham:	See patent lawsuits for Smithkline Beecham

Drugs and US Patents for Smithkline Beecham

+ Get email alerts for changes to this table

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Smithkline Beecham	COREG CR	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	022012-001	Oct 20, 2006	AB	RX	Yes	No	8,101,209*PED	➤ Sign Up			Y	➤ Sign Up
Smithkline Beecham	COREG	carvedilol	TABLET;ORAL	020297-001	Sep 14, 1995	AB	RX	Yes	No		➤ Sign Up				➤ Sign Up
Smithkline Beecham	COREG CR	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	022012-003	Oct 20, 2006	AB	RX	Yes	Yes	7,268,156*PED	➤ Sign Up			Y	➤ Sign Up
Smithkline Beecham	COREG CR	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	022012-003	Oct 20, 2006	AB	RX	Yes	Yes	8,101,209*PED	➤ Sign Up			Y	➤ Sign Up
Smithkline Beecham	COREG	carvedilol	TABLET;ORAL	020297-004	May 29, 1997	AB	RX	Yes	No		➤ Sign Up				➤ Sign Up
Smithkline Beecham	COREG CR	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	022012-004	Oct 20, 2006	AB	RX	Yes	No	8,101,209*PED	➤ Sign Up			Y	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Expired US Patents for Smithkline Beecham

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Smithkline Beecham	COREG CR	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	022012-002	Oct 20, 2006	4,503,067*PED	➤ Sign Up
Smithkline Beecham	LOVAZA	omega-3-acid ethyl esters	CAPSULE;ORAL	021654-001	Nov 10, 2004	5,698,594	➤ Sign Up
Smithkline Beecham	COREG	carvedilol	TABLET;ORAL	020297-004	May 29, 1997	5,760,069*PED	➤ Sign Up
Smithkline Beecham	AXID	nizatidine	CAPSULE;ORAL	019508-001	Apr 12, 1988	4,382,090	➤ Sign Up
Smithkline Beecham	COREG	carvedilol	TABLET;ORAL	020297-003	Sep 14, 1995	4,503,067*PED	➤ Sign Up
Smithkline Beecham	COREG CR	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	022012-002	Oct 20, 2006	5,760,069*PED	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Paragraph IV (Patent) Challenges for SMITHKLINE BEECHAM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Capsules	10 mg and 20 mg	➤ Subscribe	2008-03-18
➤ Subscribe	Extended-release Capsules	80 mg	➤ Subscribe	2007-11-19
➤ Subscribe	Capsules	1 g	➤ Subscribe	2008-11-10
➤ Subscribe	Extended-release Capsules	40 mg	➤ Subscribe	2007-12-21
➤ Subscribe	Oral Solution	15 mg/mL	➤ Subscribe	2008-05-14

International Patents for Smithkline Beecham Drugs

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Japan	2013241450	➤ Sign Up
Japan	2011088917	➤ Sign Up
New Zealand	537161	➤ Sign Up
Canada	2563689	➤ Sign Up
South Korea	20130042047	➤ Sign Up
South Korea	20100063825	➤ Sign Up
Country	Document Number	Estimated Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant

US Department of Justice

QuintilesIMS

Chinese Patent Office

Mallinckrodt

Citi

Julphar

Dow

Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.